About Li Wang
The identification of biomarkers to stratify risk for prostate cancer patients remains an unmet medical need.
Dr. Li Wang is using bioinformatics methods to identify immune cell gene expression signatures in blood samples from castrate-resistant prostate cancer patients that predict clinical outcomes to develop a prognostic biomarker that can be used to monitor patients.
In addition, the associations between the blood-based immune signature, gene expression of immune cells that infiltrate tumors, tumor genetic mutations, and other diagnostic and prognostic patient biomarkers will be assessed to identify mechanisms that regulate the immune signature.
Is successful, this project will result in the development of a blood-based biomarker to stratify a patient’s risk for lethal prostate cancer.
What this means for patients: Developing minimally invasive methods to prognosticate and monitor patients is a critical need.Dr. Wang will generate a blood-based immune biomarker to predict survival of patients with advanced, metastatic prostate cancer, which will improve clinical management of the disease.
2014 Richard and Ellen Sandler-PCF Young Investigator
Li Wang, PhD
Icahn School of Medicine at Mount Sinai
William Oh, MD and Eric Schadt, PhD
Integrative Genomics Study of Immune Signatures in Blood and Tumor Tissue for Prostate Cancer